2022 Fiscal Year Final Research Report
Studies of the HER2-CD239 complex on proliferation and adhesion of cancer cells
| Project/Area Number |
20K07622
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 50010:Tumor biology-related
|
|---|
| Research Institution | Tokyo University of Pharmacy and Life Science |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2020-04-01 – 2023-03-31
|
| Keywords | 細胞接着 / 基底膜 / ラミニン / CD239 / HER2 / 癌 |
|---|
| Outline of Final Research Achievements |
Resistance of cancer cells to anticancer drugs suggests the existence of mechanisms that can potently promote cell proliferation. Proliferation of cancer cells is closely involved in the cell adhesion to extracellular matrices. The cell adhesion to substrate is further thought to be associated with resistance of cancer cells to anticancer drugs. However, the mechanisms linking between cancer cell proliferation and adhesion are not fully understood. In this study, to clarify the mechanism, we focused on the HER2-CD239 complex at cancer cell surface. In the complex, HER2 is associated with cancer cell proliferation and CD239 binds to laminin α5 chain. We also investigated the functions of CD239 in skeletal muscle and its ligand, laminin-521, in the glomerulus.
|
| Free Research Field |
生化学
|
| Academic Significance and Societal Importance of the Research Achievements |
多細胞生物の機能的な組織は、細胞と細胞の接着だけではなく、細胞と細胞外基質との基質接着が求められる。また癌組織では、癌細胞の基質接着が細胞増殖および抗癌剤耐性に関連すると考えられている。研究代表者は、乳癌の悪性化の指標であるHER2とCD239による複合体を見出してきた。CD239は、細胞外基質であるラミニンα5鎖の特異的な受容体であり、細胞を接着させることができる。本研究により、HER2による細胞増殖を支えるCD239の基質接着メカニズムが明らかになれば、HER2標的抗体薬に対する癌細胞の耐性だけでなく、機能的な組織の基質接着メカニズムの解明につながると期待される。
|
